Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04855617 · ClinicalTrials.gov registry record
Symptom Burden in Patients Treated With Ocrelizumab for Multiple Sclerosis
A clinical trial, sponsored by NYU Langone Health.
- Completed
- Registry status
- 122
- Enrollment target
NCT04855617 is a clinical trial that has completed, run by NYU Langone Health. The registered enrollment target is 122 participants.
The verdict
NCT04855617 has completed, sponsored by NYU Langone Health.
- COMPLETED
- Registry status
- 122 participants
- Enrollment target
Study Summary
This study is designed to determine whether symptom burden differs by time to infusion.
Interventions
- DRUG Ocrelizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 122 participants |
| Start Date | 2020-10-26 |
| Est. Completion | 2022-10-01 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04855617
The ClinicalTrials.gov registry entry for NCT04855617 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 122 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is NYU Langone Health, which has 1,164 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Ocrelizumab is the first listed.
NCT04855617 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04855617 about?
NCT04855617 is a clinical study titled "Symptom Burden in Patients Treated With Ocrelizumab for Multiple Sclerosis". This study is designed to determine whether symptom burden differs by time to infusion.
What is the current status of trial NCT04855617?
This trial is currently completed. The enrollment target is 122 participants. The study started on 2020-10-26. Estimated completion is 2022-10-01.
What interventions are being tested in trial NCT04855617?
The interventions under investigation include: Ocrelizumab (DRUG).
Who is sponsoring clinical trial NCT04855617?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.